Research & Development
What is AbIMP® Technology?
AbIMP® is a novel discovery platform that utilises monoclonal antibodies as selective inhibitors of previously intractable metzincin protease targets thereby offering new possibilities… Read more »
The ADAMs Family of Sheddases – Emerging Therapeutic Targets
The ADAMs gene family of cellular sheddases are exciting, new therapeutic targets and biomarkers emerging within several clinical arenas. ADAM is an acronym… Read more »
ADAM15, A Novel Target for Anti-angiogenesis Therapy
ADAM15 is a “sheddase” known to promote pathological angiogenesis in models of ocular neovascular disease and whose expression correlates strongly with the progression… Read more »
News
VASGEN Wins Therapy Accelerator Funding
August 19th, 2022
London UK, 19th August 2022: Vasgen Limited (“Vasgen” or “the Company”), a speciality biotech company, reports successfully competing in the Hertfordshire Science Partnership… Read more »
VASGEN Achieves Proof of Concept for Pre-Clinical Ocular R & D Programme-Two Further Patents Granted
July 17th, 2017
London UK, 17th July 2017: Vasgen Limited (“Vasgen” or “the Company”), a new speciality biotech company, reports that it has successfully completed proof… Read more »
VASGEN Shortlisted to Present at Innovate UK Health & Life Science Investment Showcase
May 4th, 2016
London UK, May 4th 2016: Vasgen Limited (“Vasgen” or “the Company”), a new speciality biotech company, reports that it has been shortlisted to… Read more »